Identifying leukemia-specific neoepitopes from next-generation sequencing data to develop targeted immunotherapy for pediatric acute myeloid leukemiaig
MA Biernacki, M Bleakley, T Cunningham… - Biology of Blood and …, 2016 - tctjournal.org
Although allogeneic hematopoietic stem cell transplantation (HCT) can cure patients with
chemotherapy-refractory acute myeloid leukemia (AML), post-HCT relapse remains common
and extremely challenging to resolve. T cell immunotherapy could augment HCT efficacy by
inducing deeper remissions pre-HCT to prevent relapse, or to treat or prevent relapse post-
HCT. However, development of T cell immunotherapy for AML has been limited by a paucity
of antigens established to be safe and effective T cell targets. Recurrent AML-specific …
chemotherapy-refractory acute myeloid leukemia (AML), post-HCT relapse remains common
and extremely challenging to resolve. T cell immunotherapy could augment HCT efficacy by
inducing deeper remissions pre-HCT to prevent relapse, or to treat or prevent relapse post-
HCT. However, development of T cell immunotherapy for AML has been limited by a paucity
of antigens established to be safe and effective T cell targets. Recurrent AML-specific …